Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
Revolution Medicines announced that the New England Journal of Medicine published Phase 1/2 data for daraxonrasib in patients with metastatic RAS mutant pancreatic ductal adenocarcinoma (PDAC). The publication highlights findings that supported the initiation of the Phase 3 registrational trial RASolute 302, which recently reported topline results showing an unprecedented overall survival benefit versus standard chemotherapy.
Key figures
- Drug Name
- Daraxonrasib
- Phase Of Trial
- Phase 1/2
- Trial id
- NCT05379985
- Phase 3 trial name
- RASolute 302
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.